GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B1364 ScopineSummary: α1-adrenergic receptor agonist -
C6723 Theophylline-7-acetic acid -
C3864 2-chloro-3-DeazaadenosineSummary: adenosine receptors agonist -
B2251 NaratriptanTarget: 5-HT1 ReceptorSummary: selective 5-HT1 receptor subtype agonist -
B1363 Phentolamine MesylateSummary: Alpha 1/2-blocking agent -
C3278 ProxyphyllineSummary: A1 adenosine receptor antagonist -
B2250 LY310762Summary: 5-HT1D receptor antagonist -
B1362 NaftopidilSummary: α1-adrenergic receptor antagonist -
C3068 MRS1523Summary: adenosine A3 receptor antagonist -
B1361 Medetomidine HClSummary: Selective α2-adrenoceptor agonist
